8-K: Intellia's MAGNITUDE-2 Clinical Hold Lifted by FDA

Intellia Therapeutics announced the FDA has removed the clinical hold on its MAGNITUDE-2 Phase 3 trial for ATTRv-PN, allowing patient enrollment to resume.

Summary

• The U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for Intellia's MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
• The clinical hold was initially imposed on October 29, 2025, for both the MAGNITUDE-2 and MAGNITUDE Phase 3 clinical trials.
• The hold followed the observation of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial (for ATTR-CM) and subsequently passed away.
• Intellia has aligned with the FDA on certain study modifications and mitigation measures for MAGNITUDE-2, which include enhanced safety monitoring of liver laboratory tests.
• The company is engaged with clinical trial investigators, ethics committees, international regulatory authorities, and other stakeholders to resume enrollment activities for MAGNITUDE-2 as quickly as possible.
• The MAGNITUDE Phase 3 clinical trial of nex-z for patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) remains on clinical hold, with ongoing engagement with the FDA.
• Intellia plans to provide an update on the MAGNITUDE program once alignment has been achieved on the path forward.
• The target enrollment for the MAGNITUDE-2 trial has been increased from approximately 50 patients to approximately 60 patients with ATTRv-PN.
• Primary endpoints for the MAGNITUDE-2 study are a change in modified neuropathy impairment score and a change in serum TTR levels.

Sentiment

Score: 8

Explanation: The lifting of a clinical hold on a Phase 3 trial is a very positive development, significantly de-risking a key program. While the other trial remains on hold, the resolution for MAGNITUDE-2 is a strong positive signal for the company's ability to address regulatory concerns and advance its lead candidate.

Positives

• The FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial for ATTRv-PN, allowing patient enrollment and dosing to resume.
• Intellia has aligned with the FDA on study modifications and mitigation measures for MAGNITUDE-2, including enhanced safety monitoring, providing a clear path forward for this trial.
• Nexiguran ziclumeran (nex-z) has received Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) Designation from the U.S. FDA and an Orphan Drug Designation (ODD) from the European Commission.

Negatives

• The MAGNITUDE Phase 3 clinical trial for ATTR-CM remains on clinical hold, delaying its progress.
• The initial clinical holds were imposed following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient dosed with nex-z in the MAGNITUDE trial, who subsequently passed away.

Risks

• Uncertainties related to the ability to resume the MAGNITUDE and MAGNITUDE-2 trials, despite the MAGNITUDE-2 hold being lifted.
• Regulatory agencies' evaluation of regulatory filings and other information related to product candidates, including nex-z.
• Uncertainties related to the authorization, initiation, and conduct of studies and other development requirements for product candidates, including regulatory approvals to conduct clinical trials.
• The risk that any one or more of Intellia's product candidates, including nex-z, will not be successfully developed and commercialized.
• Risks related to the ability to protect and maintain intellectual property position.
• Risks related to valid third-party intellectual property.
• Risks related to relationships with third parties, including licensors and licensees.
• The risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or other product candidates.
• Risks related to reliance on collaborations, including that the collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful.

Future Outlook

Intellia plans to resume patient enrollment for the MAGNITUDE-2 trial as quickly as possible and is actively engaging with the FDA regarding the ongoing clinical hold for the MAGNITUDE trial, with an update expected once alignment is achieved.

Management Comments

• "We appreciate the FDA's expeditious review of our submission and ongoing engagement and thank our study investigators and patients for their continued participation."
• "With the clinical hold for MAGNITUDE-2 lifted, our team is focused on resuming patient enrollment as quickly as possible as we seek to advance this potential one-time treatment option for people living with ATTRv-PN."

Industry Context

The lifting of a clinical hold for a CRISPR-based gene editing therapy in a Phase 3 trial is a significant event in the biotechnology and gene therapy sector. It signals progress in addressing safety concerns for a novel therapeutic modality and could bolster confidence in the broader CRISPR-based drug development landscape, particularly for rare diseases like ATTR amyloidosis. The continued hold on the ATTR-CM trial, however, highlights the ongoing scrutiny and challenges in developing these advanced therapies.

Comparison to Industry Standards

• Nexiguran ziclumeran (nex-z) utilizes Nobel Prize-winning CRISPR/Cas9 gene editing technology, positioning it at the forefront of genetic medicine, similar to other leading gene editing companies like CRISPR Therapeutics and Editas Medicine, which are also advancing therapies based on CRISPR technology.
• The development of a one-time treatment for ATTR amyloidosis, if successful, would represent a significant advancement over existing chronic therapies, potentially setting a new standard for patient care in this indication, comparable to the impact of one-time gene therapies in other rare diseases.
• The FDA's rigorous review process and imposition of clinical holds, followed by the requirement for enhanced safety monitoring, are standard industry practices for novel therapies, especially those with potential serious adverse events, ensuring patient safety and data integrity.

Stakeholder Impact

• Shareholders: Positive impact due to reduced regulatory risk and advancement of a key clinical program, potentially leading to increased share price.
• Patients (ATTRv-PN): Positive impact as the trial for a potential one-time treatment can resume, offering hope for a new therapeutic option.
• Patients (ATTR-CM): Continued uncertainty and delay for those awaiting treatment from the MAGNITUDE trial.
• Clinical Trial Investigators/Ethics Committees: Engagement required to resume enrollment activities.
• Regeneron Pharmaceuticals, Inc. (Collaborator): Positive impact on the collaboration for nex-z development.

Next Steps

• Resume patient enrollment and dosing for the MAGNITUDE-2 Phase 3 clinical trial as quickly as possible.
• Continue engagement with the FDA regarding the clinical hold on the MAGNITUDE Phase 3 clinical trial for ATTR-CM.
• Provide an update on the MAGNITUDE program once alignment with the FDA has been achieved.

Key Dates

Recommendation

The FDA's decision to lift the clinical hold on the MAGNITUDE-2 Phase 3 trial for ATTRv-PN is a significant de-risking event for Intellia Therapeutics. This allows a critical late-stage program to resume, validating the company's ability to address safety concerns and progress its CRISPR-based therapy. While the MAGNITUDE trial for ATTR-CM remains on hold, the resolution for ATTRv-PN provides a clear positive catalyst and reduces a major overhang on the stock, making it an attractive entry point for investors.

Keywords

Intellia Therapeutics, NTLA, FDA, Clinical Hold, MAGNITUDE-2, nexiguran ziclumeran, nex-z, ATTRv-PN, CRISPR, Gene Editing, Phase 3, Clinical Trial, Orphan Drug, RMAT Designation, Regeneron